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54 N.S. Elshaer et al.IgE; eosinophil count and GSTM1 and GSTT1 null polymorphism as risk factors for the develop-
ment of bronchial asthma.
Methods: Acase control studywas conducted inwhich 100workerswith bronchial asthmawere com-
pared to 100 non asthmatic controls regarding their occupational characteristics, bronchodilator
responsiveness, blood analysis for eosinophil count, total serum IgE, GSTM1 andGSTT1 genotypes.
Results: Exposure to irritants and allergens were signiﬁcantly higher among workers with bronchial
asthma compared to controls (86% vs. 64%, respectively, P= 0.00). Moreover, workers exposed to
irritants were found to be 4 times at a higher risk of developing bronchial asthma, and those exposed to
high molecular weight (HMW), and/or low molecular weight (LMW) were about three times at a
higher risk of developing bronchial asthma. There was no signiﬁcant difference detected between
the cases of bronchial asthma and the controls regarding the frequency of theNull-genotype for either
GSTT1 or GSTM1. However, the frequency of combined Null-genotype for both GSTT1 and
GSTM1 was signiﬁcantly higher in asthmatic workers than in controls. A signiﬁcant positive correla-
tion was found between total serum IgE level and pre-bronchodilator FEV1/FVC% (r= 0.29, and
P= 0.03).
Conclusion: Occupational exposure to irritants and/or allergens is a signiﬁcant risk factor for the
occurrence of bronchial asthma among workers. On the other hand, eosinophil count and total serum
IgE neither predicts the occurrence of bronchial asthma nor affects the severity and pattern of the dis-
ease amongworkers with bronchial asthma.Moreover, the present study concluded that GSTM1 and
GSTT1 Null-genotypes are not likely to act as risk factors for the development of bronchial asthma.
However, combinedGSTT1andGSTM1Null-genotypeswere considered as a potential risk factor for
the development of bronchial asthma.
ª 2011 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
All rights reserved.1. Introduction
Bronchial asthma is a state of airﬂow limitation and/or bron-
chial hyper responsiveness (BHR) resulting from a persistent
inﬂammatory process in response to a number of stimuli in a
genetically susceptible individual. Simple deﬁnition of occupa-
tional asthma (OA) is asthma due to causes and conditions
attributable to a particular working environment and not to
stimuli encountered outside the workplace.1
There is more emphasis on deﬁning OA based on mech-
anism. Thus, allergic-type OA involves allergic/immunologic
sensitization to a substance or material present in the work-
site and excluding other occupational causes of variable air
ﬂow limitation not due to sensitization. For the allergic type
of OA, a key clinical feature is that asthma develops after
the passage of a latent period. Exposures that lead to
allergic-type OA are called allergens which are either of high
or low molecular weight substances. High molecular weight
(HMW) allergens are substances of animal origin (such as
animal hair, urine or saliva proteins, epidermal squamae,
small insects, molds, dander, bacteria, protein dust, and
mites) and vegetable origin (such as wood or wood prod-
ucts, cotton, ﬂax, hemp, grain, ﬂour, and latex). Low molec-
ular weight allergens are substances of chemical origin,
metals and pharmaceuticals.2
Nonallergic OA (e.g., without latency) is also called irritant-
type OA. This type of asthma is usually of sudden-onset and
develops after high-level workplace irritant exposure; it devel-
ops abruptly without a signiﬁcant latent period. The absence
of a latent period is a critical clinical feature that an allergic
mechanism, sensitization, is not operative.3 Allergic-type OA
and work-aggravated asthma occurs much more frequently
than irritant-induced asthma. The prevalence of irritant-in-
duced asthma is 6–22% of all work-related cases.3,4 Exposures
that lead to irritant-type OA are inhaled irritants.2Workers most commonly reported to surveillance programs
for OA include paint sprayers, bakers, nurses, animal handlers,
welders, farmers, waiters, cleaners, laboratory and dental tech-
nicians, forestry workers, and workers in chemical, plastics,
rubber, textile, and electrical industries.5
Atopy is the most signiﬁcant risk factor for asthma devel-
opment, with approximately 85% of children who develop
asthma and 40–50% of adults with new-onset asthma having
an allergic response to aeroallergens.6–8 Atopy represents a
complex gene-environment interaction in which environmental
antigens interact with the immune system, producing atopic
(IgE) responses.9 Several studies reveal a link between IgE
and asthma.7,10,11 Some studies demonstrated that elevated
pre-employment total serum IgE is a risk factor.12
In the context of new candidate genes for asthma, the
presence of airway inﬂammation is an important biochemical
feature of asthma. There is evidence that a genetic predisposi-
tion may alter the capability of the airway to protect itself
against inhaled toxic substances from the environment. Oxida-
tive stress, with the formation of reactive oxygen species
(ROS), is a key component of inﬂammation.13,14 Although
host antioxidant defenses should detoxify ROS, individuals
differ in their ability to deal with an oxidant burden, and such
differences are in part genetically determined. Inability to
detoxify ROS should perpetuate the inﬂammatory process,
activate bronchoconstrictor mechanisms, and precipitate asth-
ma symptoms.14
Among lung antioxidants, glutathione is a key element and
considered a susceptibility factor for OA. In humans, glutathi-
one S-transferases (GSTs) represent a large and diverse super
family of enzymes which play an important role in the func-
tioning of antioxidant defenses.15 Accordingly, members of
the glutathione-S-transferase (GST) supergene family are
potential candidates for genetic studies for their linkage to
asthma, as enzymes encoded by them are critical in the
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strates a wide variety of products of oxidative stress.16 The
GSTM1 and GSTT1 are the code names for GSTmu and
GSTtheta enzymes that belong to the glutathione S-transferase
(GST) genes super family.15 They have been known to abolish
enzymes activity and increase susceptibility to oxidative stress.
Polymorphic variants in the class glutathione-S-transferase lo-
cus GSTM1 and GSTT1 inﬂuence how an individual handles
an inﬂammatory-derived ROS burden.16 Data, from previous
studies, showed that particular genotypes are associated with
an increased susceptibility to and/or poor outcome in several
inﬂammatory pathologies.17
Few studies examined the hypothesis that polymorphism in
the GSTM1, GSTT1, and GSTP1 loci is associated with asth-
ma and related phenotypes. Studies have reported contradic-
tory results regarding any association between GST gene
polymorphism and asthma.17–23
Objective assessments of pulmonary function are necessary
for the diagnosis of asthma because medical history and phys-
ical examination are not reliable means of excluding other
diagnoses or of characterizing the status of lung impairment.
Although physicians generally seem able to identify a lung
abnormality as obstructive, they have a poor ability to assess
the degree of airﬂow obstruction or to predict whether the
obstruction is reversible.6 Spirometry measurements – forced
expiratory volume at one second (FEV1), forced vital capacity
(FVC), FEV1/FVC – before and after the patient inhales a
short-acting bronchodilator should be done to determine
whether there is airﬂow obstruction, its severity, and whether
it is reversible over the short term.24,25 A reduced ratio of
FEV1, and FEV1/FVC relative to references or predicted val-
ues indicates airﬂow obstruction, whereas a proportionately re-
duced FVC with a normal or increased FEV1/FVC ratio
suggests a restrictive pattern. The severity of airﬂow obstruction
is evaluated by comparison of the patient’s results with refer-
ence values based on age, height, sex, and race.26
Many workers in Alexandria are exposed to varieties of
occupational and environmental allergens and/or irritants that
predispose them to the development of bronchial asthma. In
spite of the extent of occupational exposures and the fact that
bronchial asthma and work-related asthma are nowadays of-
ten preventable by early detection of genetically predisposed
individuals and cessation of exposure to the causative agent,27
yet, little attention has been given to the problem; as the Egyp-
tian national table for prescribed occupational diseases till now
does not include occupational asthma, and consequently, pre-
placement examination for bronchial asthma is till date not
conducted. The present study was conducted to determine
the role of occupational exposure as a determinant of occur-
rence of bronchial asthma and to assess the possible role of to-
tal serum IgE; eosinophil count and GSTM1 and GSTT1 null
polymorphism as risk factors for the development of bronchial
asthma. The speciﬁc objectives of the current study were: (1)
describe the relationship between occupational exposures and
occurrence of bronchial asthma; (2) study the pattern and
severity of bronchial asthma among workers; (3) reveal the
relationship between eosinophil count, total serum IgE anti-
bodies and bronchial asthma; and (4) study of GSTT1 and
GSTM1 genotypes among the workers with bronchial asthma
and non asthmatic controls to determine the potential role of
these genes Null-genotype as a risk factor in occurrence of
bronchial asthma.2. Methods
The case control approach was adopted for this study to esti-
mate the odds ratio, and test the hypothesis that asthma is
caused by certain etiological factors such as occupational,
immunologic and genetic characteristics.
The study included 100 male workers with bronchial asth-
ma and 100 control workers who attended the Health Insur-
ance Clinics during 8 month ﬁeld work period of the study
from January throughout August 2009. The unit of observa-
tion was a worker suffering from bronchial asthma as well as
his free matched (age group) worker.
A bronchial asthma patient was included in the study when
he was (a) a male; (b) able to perform technically acceptable
pulmonary function tests; (c) 40 years old or more; (d) suffer-
ing from recurrent episodes of chest wheezing, breathlessness,
chest tightness and coughing particularly at night or in the
early morning; (e) non-smokers or ex-smokers with less than
10 packs/year history; and (f) clinically stable with no respira-
tory exacerbations for six weeks prior to inclusion in the study
and with no changes in chronic medication during this period.
Respiratory exacerbations were deﬁned as an increase in
breathlessness, sputum volume or sputum purulence from the
baseline requiring treatment with prednisone and/or
antibiotics.
The participant was included in the control group when he
was (a) a male; (b) able to perform technically acceptable pul-
monary function tests; (c) 40 years old or older; (d) had to be a
lifetime non-smoker or an ex-smoker with less than 10 packs/
year history; (e) had no respiratory symptoms or disease and
never reporting physician-diagnosed respiratory disease, dysp-
nea, morning cough or wheeze.
Workers with bronchial asthma and controls were sub-
jected to the following data collection tools:
(a) Interviewing schedule: Workers were interviewed in Alex-
andria Health Insurance Outpatient Clinics by a special
interviewing schedule that was designed to obtain data
about personal characteristics, family, medical and occu-
pational histories; it was based on the British Medical
Research Council Questionnaire (BMRC)28 and the
allergy questionnaire29 with minor modiﬁcations to some
questions to be adjusted to the Egyptian workers (can
be obtained from the authors upon request).
(b) Anthropometric measurements: Including weight and
height.30
(c) Spirometry: All workers included in the study underwent
spirometry at the Industrial Medicine Unit afﬁliated to
the Department of Community Medicine in the Alexan-
dria Faculty of Medicine.The equipment used was Spi-
rometer ST-95 version 1.1A manufactured by Fukuda
Sangyo Co., Ltd. Japan in 1998. It is a computerized spi-
rometer which can produce both volume-time and ﬂow-
volume curves. The used spirometer and the performance
of the maneuver met recommendations of the American
Thoracic Society (ATS) and the European Society of
Clinical Respiratory Physiology.31,32 Maneuver of forced
expiration was explained for the participant by the
investigator. The test procedure was explained to each
participant. The participant performed the test while
seated. He was asked to take 3 deep breaths, then, to ﬁll
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then he was asked to breathe out as fast and explosive as
possible till he reached his residual volume (RV). Each
participant performed at least 3 test maneuvers. If the per-
formance was unsatisfactory, the participant was asked to
repeat it again. Maximum number of maneuvers was 7
times, the best 3 traces were selected provided that there
was good reproducibility between the best 3 trials, i.e.,
the variability between them was less than 5% for the
FVC and FEV1 indices and 10% for the PEF index. The
highest of the three trials for each index ‘‘best test’’ was
recorded as the ﬁnal value.31 For analysis, the best
FEV1 and forced vital capacity (FVC) were chosen regard-
less of the curve. The ‘best test’ curve was selected from
the largest sum of FEV1 and FVC. All other lung function
parameters selected for analysis were taken from the ‘best
test’ curve.
Pre and post-bronchodilator lung function testing: among
workers with bronchial asthma, bronchodilator treatment
was withdrawn prior to pulmonary function testing
according to standard practice (immediate release theoph-
ylline: 24 h, long-acting b2 agonist: 12 h, short-acting b2
agonist: 6 h and short acting anticholinergic: 8 h).The
investigator conducted maximal in-and expiratory ﬂow
volume curves with the participants before (‘pre’) and
20 min after (‘post’) administration of 2 puffs (400 lg) sal-
butamol. The medication was given via a metered dose
inhaler with a large volume spacer (Volumatic, Glaxo-
SmithKline).33
Bronchodilator responsiveness (BDR) was calculated
according to the following criteria: (1) post-bronchodila-
tor FEV1P 80% predicted and FEV1/FVC ratioP 70%;
(2) FEV1 change from initial (=post FEV1  pre FEV1/
pre FEV1 · 100)P 12%; (3) FEV1 absolute change
(=post FEV1  pre FEV1)P 200 mL; and (4) FEV1
change from predicted (=post FEV1  pre FEV1/pre-
dicted FEV1 · 100)P 9%.
The severity of bronchial asthmawas determined according
to the guidelines of the National Heart, Lung, and Blood
Institute in 2007.34 This classiﬁcation was based on the fol-
lowing components: (a) symptoms, such as nighttime awak-
ening, need for short-acting b2 agonist (SABA) for quick
relief of symptoms and work days missed; (b) activity levels
which means the ability to engage in normal daily activities
or in desired activities and (c)lung function,measured by spi-
rometry: FEV1, FVC and FEV1/FVC; the severity of air-
ﬂow obstruction is classiﬁed into mild, moderate and
severe obstruction when the FEV1 is P80%, 60% to
<80% and <60% of predicted values, respectively.34
(d) Immunological investigations: Three milliliters of periphe-
ral blood was collected, from participants who gave full
agreement, in an EDTA-containing vacutainer and the
following immunological investigations were done: (1)
eosinophil count; eosinophilia was considered when the
eosinophil count was >0.8 · 103 cells/lL35; and (2) total
serum IgE level using BN ProSpec of Dade Behring Mar-
burg GmbH.36 In adults, total serum IgE values of
<100 IU/mL are considered normal values.37
(e) GSTM1 and GSTT1 genotyping: The genomic DNA for
genotyping was isolated from 1 mL of peripheral blood
collected in an EDTA containing vacutainer using alcohol
precipitation DNA extraction method (Wizard genomicDNA extraction Kit, Promega).38 The GSTM1 and
GSTT1 Null-genotypes were detected using a multiplex
polymerase chain reaction (PCR) method.39 Brieﬂy,
100 ng of DNA were ampliﬁed in a 50-lL multiplex reac-
tion mixture containing 10 pmol of each of the following
primers:
 GSTM1 primers:GSTM1-F:TTCCTCACTGGTCCTCA-
CATCTCGSTM1-R: TCACCGGATCATGGCCAGCA
 GSTT1 primers:GSTT1-F: GAACTCCCTGAAAAGC-
TAAAGCGSTT1-R: GTTGGGCTCAAATATACGGT
GG.
The ALBUMIN gene was also ampliﬁed as an internal con-
trol with 5 pmol of each of its primers (Alb-F: GCCCT
CTGCTAACAAGTCCTAC and Alb-R: GCCCTAAAAAG
AAAATCGCCAATC). The PCR reaction contained 3.5 mM
MgCl2, 200 lM dNTPs, 5 lL 10X PCR buffer, and 2U TaqD-
NA polymerase. Inclusion of negative control in all PCR reac-
tions was included to ensure exclusion of any contaminations.
The PCR protocol included an initial melting temperature
of 94 C for 5 min followed by 35 cycles of denaturation at
94 C for 40 s, annealing at 60 C for 40 s and extension at
72 C for 1 min. A ﬁnal 7-min extension step at 72 C termi-
nated the process. The PCR products were analyzed on 2%
agarose gels. A fragment of 215 bp indicated the presence of
GSTM1; a fragment of 480 bp indicated the presence of
GSTT1; and a fragment of 380 bp indicated positive internal
control of albumin gene ampliﬁcation. The subjects were clas-
siﬁed as either (+) for each genotype when a PCR product is
produced or () when they showed a Null-genotype for each
of GSTM1 and GSTT1, provided that there is a PCR product
for the internal control (Fig. 1). In case the internal control did
not work, the sample was repeated.
2.1. Statistical analysis
The collected data were coded and typed onto computer ﬁles
using. SPSS/Pc + software program version 18.0.40 Descrip-
tive statistics including frequency, percentages, arithmetic
mean (X), and standard deviation (SD) were used to describe
workers with bronchial asthma and controls. The study also
used analytic measures such as student t-test, v2 test, and
non-parametric tests. Correlations between spirometry, eosin-
ophil count, and total serum IgE using non-parametric Spear-
man’s correlation were also included in the present study. The
level of signiﬁcance selected for this study was the 0.05 level.
2.2. Ethical clearance
The overall study objectives and procedures were explained
and consents were obtained from all participants in the study.
All collected data were dealt with great conﬁdentially. The
study was approved by Alexandria Faculty of Medicine Re-
search Ethics Committee.
3. Results
3.1. Population personal characteristics
There was no signiﬁcant difference between workers with
bronchial asthma and controls regarding their mean age,
Table 1 Personal and occupational characteristics of workers with bronchial asthma and controls.
Characteristics Workers with BA (n= 100) Controls (n= 100) Test of sig. P-value
Age
Min–max 40–76 41–70 t= 1.40
0.16X ± SD 59.00 ± 11.03 57.16 ± 7.04
Height (m)
Min–max 1.57–1.89 1.56–1.97 t= 1.11
0.26X± SD 1.70 ± 0.11 1.86 ± 0.50
Weight (kg)
Min–Max 59.00–91.00 57.00–98.00 t= 1.17
0.24X ± SD 74.95 ± 8.77 76.44 ± 9.12
BMI
Min–Max 18.62–47.00 18.01–36.16 t= 0.57
0.56X± SD 26.41 ± 6.50 25.93 ± 5.10
Education
Illiterate 40 32 X2 = 13.08
0.01Read & write 18 18
Basic 36 28
Secondary – 8
University 6 14
Smoking habit
Non-smoker 47 61 X2 = 1.19
0.08Ex-smoker 53 39
Duration of employment (year)
Min–Max 20.00–45.00 19.00–38.00 t= 1.37
0.17X± SD 25.22 ± 9.46 26.67 ± 4.67
Daily working hours (h)
Min–Max 6.00–14.00 8.00–12.00 t= 1.34
0.18X± SD 9.16 ± 1.97 9.52 ± 1.82
Working status
Actually working 40 41 X2 = 0.08
0.77On pension 60 59
Use of PPE
Yes 16 26 X2 = 3.01
0.08No 84 73
BA: Bronchial asthma.
Figure 1 Captured gel image of Multiplex PCR genotyping assay for detection of GSTT1 and GSTM1 gene deletion using 2% agarose.
The subjects were classiﬁed as either (+), when at least one specimen of the gene was detected, or () when they showed a null genotype.
Examples; participant No.11 is GSTT1 (+) and GSTM1(); participant No.12 is GSTT1() and GSTM1(); and participant No.17 is
GSTT1() and GSTM1(+).
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other hand, there was a signiﬁcant difference between workers
with bronchial asthma and controls regarding their education,
where workers in the control group continued their education
to the secondary and/or the university level (X2 = 13.08 and
P= 0.01) (Table 1).
3.2. Occupational exposure characteristics
There was no signiﬁcant difference between workers with
bronchial asthma and controls regarding the duration of
employment, daily working hours, working status and the
use of personal protective equipment at work (Table 1). About
one third of workers with bronchial asthma (28%) were afﬁli-
ated to textile industry followed by 18% were involved in gen-
eral public services and 16% worked in chemical industry.
The study demonstrated the distribution of workers with
bronchial asthma and controls according to their exposure sta-
tus and the nature of exposure. The study showed that 86% of
workers with bronchial asthma were exposed compared to 64%
of controls; the difference was statistically signiﬁcant where OR
was 3.46 (1.64–7.38), X2 = 12.90, and P= 0.00. Regarding the
nature of exposure among workers with bronchial asthma and
controls, signiﬁcantly increased ORs were found for exposure
to irritants (OR = 4.35); HMW allergens (OR = 3.27);
LMW (OR= 3.04); and mixed environments (OR = 3.43).
The differences were statistically signiﬁcant where X2 = 10.25
(P= 0.001); X2 = 5.59 (P= 0.018); X2 = 6.94 (P= 0.008);
and X2 = 8.0 (P= 0.005), respectively (Table 2).
3.3. Study of bronchodilator response
In the present study, the mean values and the mean percent
predicted values of pre-bronchodilator FEV1, FVC, and
FEV1/FVC% were signiﬁcantly lower in workers with bron-
chial asthma compared to controls.
Regarding the post-bronchodilator lung function indices in
the current study, the mean value and the mean percent pre-
dicted value of post-bronchodilator FEV1 were signiﬁcantly
lower in workers with bronchial asthma (2.44 ± 0.19 L, and
75.15 ± 6.80%, respectively) compared to controls (4.12 ±Table 2 Distribution of workers with bronchial asthma and contr
Nature of exposure Workers with BA (n= 100)
Not exposeda 14
Exposed 86
Irritants 22
25.58%
High molecular weight allergens
(HMW allergens)b
14
16.27%
Low molecular weight allergens
(LMW allergens)c
26
30.23%
Mixed environment
(HMW and LMW allergens)
24
27.90%
BA: Bronchial asthma.
a Unlikely to be exposed to substances associated with risk of asthma
b High molecular weight such as allergens derived from animals (roden
plants (latex, ﬂour) or biological enzymes.
c Low molecular weight allergens such as highly reactive chemicals, is
metal sensitizers.0.18 L, and 89.66 ± 4.75%, respectively) (P= 0.00). The
mean absolute change of FEV1, the mean% change of FEV1
from the initial and the mean% change of FEV1 from the pre-
dicted were signiﬁcantly higher in workers with bronchial asth-
ma (0.42 ± 0.18L, 20.64 ± 9.02%, and 12.77 ± 5.31%,
respectively) compared to controls (0.05 ± 0.14 L, 2.32 ±
1.11%, and 2.03 ± 0.93%, respectively) (P= 0.00) (Table 3).
The mean value of post-bronchodilator FVC was signiﬁ-
cantly lower in workers with bronchial asthma (3.58 ±
0.19 L) compared to controls (4.95 ± 0.15 L) (t= 56.10
and P= 0.00). The mean absolute change of FVC, the mean
% change of FVC from the initial, and the mean% change of
FVC from the predicted were signiﬁcantly higher in workers
with bronchial asthma (0.37 ± 0.12 L, 11.58 ± 4.53%, and
9.37 ± 3.10%, respectively) compared to controls (0.80 ±
0.26 L, 1.82 ± 1.27%, and 2.03 ± 0.81%, respectively)
(P= 0.00) (Table 3).
The mean value of post-bronchodilator FEV1/FVC% was
signiﬁcantly lower in workers with bronchial asthma
(68.12 ± 5.86) compared to controls (83.49 ± 3.37)
(t= 22.69 and P= 0.00). The %mean change of FEV1/
FVC from the initial, and the mean change of FEV1/FVC%
from the predicted were signiﬁcantly higher in workers with
bronchial asthma (4.66 ± 6.43 and 5.30 ± 7.33, respectively)
compared to controls (1.98 ± 1.23 and 2.21 ± 1.39, respec-
tively) (P= 0.00) (Table 3).
The current study classiﬁed workers with bronchial asthma
according to the severity of asthma; 58% of workers with
bronchial asthma in the present study had moderate persistent
bronchial asthma, 18% had mild persistent bronchial asthma,
16% had intermittent bronchial asthma and 8% had severe
persistent asthma.
3.4. Eosinophil count and total serum IgE in workers with
bronchial asthma
There was no signiﬁcant difference between workers with
bronchial asthma and controls regarding eosinophil count
and total serum IgE level (Table 4).
Regarding the bronchial asthma severity categories, about
97% of workers with moderate to severe persistent asthmaols according to exposure.
Controls (n= 100) Odds ratio Test of sig. P-value
36 3.46 (1.64–7.38) X2 = 12.90
0.0064
13
20.31%
4.35 (1.58–12.25) X2 = 10.25
0.001
11
17.18%
3.27 (1.08–10.13) X2 = 5.59
0.018
22
34.37%
3.04 (1.21–7.7) X2 = 6.94
0.008
18
28.12%
3.43 (1.32–9.01) X2 = 8.0
0.005
or to other irritating chemicals.
ts, livestock, ﬁsh, shellﬁsh, arthropods or mites); allergens derived from
ocyanates, sensitizing drugs, industrial cleaning agents, wood dusts, or
Table 3 Mean values and mean percent predicted values of post-bronchodilator (Post-BD) FEV1, FVC and FEV1/FVC in workers
with bronchial asthma and controls.
Post-BD Workers with BA (n= 100)
X± SD
Controls (n= 100)
X± SD
Test of sig. P-value
Post-BD FEV1 (L) 2.44 ± 0.19 4.12 ± 0.18 t= 81.78
0.00
Post-BD FEV1 (% predicted) 75.15 ± 6.80 89.66 ± 4.75 t= 17.48
0.00
FEV1Absolute change (L) 0.42 ± 0.18 0.05 ± 0.14 t= 16.93
0.00
FEV1% change from initial 20.64 ± 9.02 2.32 ± 1.11 t= 20.14
0.00
FEV1% change from predicted 12.77 ± 5.31 2.03 ± 0.93 t= 19.90
0.00
Post-BD FVC (L) 3.58 ± 0.19 4.95 ± 0.15 t= 56.10
0.00
Post-BD FVC (% predicted) 90.53 ± 2.94 90.51 ± 4.44 t= 0.033
0.97
FVC absolute change (L) 0.37 ± 0.12 0.80 ± 0.26 t= 26.84
0.00
FVC% change from initial 11.58 ± 4.53 1.82 ± 1.27 t= 24.77
0.00
FVC% change from predicted 9.37 ± 3.10 2.03 ± 0.81 t= 28.52
0.00
Post-BD FEV1/FVC% 68.12 ± 5.86 83.49 ± 3.37 t= 22.69
0.00
FEV1/FVC% mean change 4.66 ± 6.43 1.98 ± 1.23 Mann–Whitney = 3000
0.00
FEV1/FVC% change from predicted 5.30 ± 7.33 2.21 ± 1.39 Mann–Whitney = 3003
0.00
BA: Bronchial asthma.
Table 4 Eosinophil count and total serum IgE level among workers with bronchial asthma and controls.
Variable Workers with BA (n= 50) Controls (n= 50) OR 95% CI Tests of sig. P-value
No. % No. %
Eosinophil count (·103 cells/lL) Normal 49 98 50 100 Cannot be calculated NA Yates corrected
P= 1High 1 2 0 0
Total serum IgE level (IU/mL) Normal 22 44 15 30 0.55 0.22–1.34 0.14
High 28 56 35 70
Table 5 Eosinophil count and total serum IgE level in different bronchial asthma severity categories in workers with bronchial
asthma.
Variable Intermittent or mild persistent BA Moderate or severe persistent BA Tests of sig. P-value
No. % No. %
Eosinophil count (·103 cells/lL) Normal 17 100 32 96.9 1.0a
High 0.00 0.00 1 3.03
Total serum IgE level (IU/mL) Normal 7 41.2 15 45.45 1.0a
High 10 58.8 18 54.54
BA: Bronchial asthma.
a Fisher’s Exact test.
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high eosinophil count. According to the total serum IgE level,
54.54% of workers with moderate to severe persistent asthma
had high level of total serum IgE compared to 45.45% who
had normal level; these differences were statistically insigniﬁ-
cant (Table 5).3.5. GSTM1 and GSTT1 null polymorphism and bronchial
asthma
On studying the genotype proﬁle in a subsample of workers
with bronchial asthma and controls, the presence of GSTM1
Null-genotype was compared in both sample groups. The dif-
Table 6 Association between genotype proﬁle and bronchial asthma phenotype.
Gene Chromosomal location Polymorphism Genotype Workers with BA (n= 50) Controls (n= 50) OR 95% CI P-value
No. (%) No. (%)
GSTM1 1p13 Null allele Null 29 (58%) 26 (52%) 0.78 0.33–1.86 0.54
WT 21 (42%) 24 (48%)
GSTT1 22q11 Null allele Null 12 (24%) 5 (10%) 0.35 0.1–1.21 0.06
WT 38 (76%) 45 (90%)
BA: Bronchial asthma.
Table 7a Association between GSTM1 genotype proﬁle and bronchial asthma phenotype among exposed workers with bronchial
asthma and exposed controls.
Gene Chromosomal location Polymorphism Genotype Workers with BA (n= 40) Controls (n= 31) OR 95% CI P-value
No. (%) No. (%)
GSTM1 1p13 Null allele Null 23 (57.5%) 18 (58%) 0.97 0.37–2.52 0.96
WT 17 (42.5%) 13 (41.9%)
BA: Bronchial asthma.
Table 7b Association between GSTM1 genotype proﬁle and bronchial asthma phenotype among non-exposed workers with
bronchial asthma and non-exposed controls.
Gene Chromosomal location Polymorphism Genotype Workers with BA (n= 10) Controls (n= 19) OR 95% CI P-value
No. (%) No. (%)
GSTM1 1p13 Null allele Null 6 (60%) 8 (42.1%) 2.06 0.43–9.80 0.35
WT 4 (40%) 11 (57.8%)
BA: Bronchial asthma.
Table 8a Association between GSTT1 genotype proﬁle and bronchial asthma phenotype among exposed workers with bronchial
asthma and exposed controls.
Gene Chromosomal location Polymorphism Genotype Workers with BA (n= 40) Controls (n= 31) OR 95% CI P-value
No. (%) No. %
GSTT1 22q11 Null allele Null 8 (20%) 3 (9.67%) 2.33 0.56–9.65 0.23
WT 32 (80%) 28 (90.32%)
BA: Bronchial asthma.
60 N.S. Elshaer et al.ference in the frequency of GSTM1 Null-genotype between
workers with bronchial asthma and controls was insigniﬁcant
(58% and 52%, respectively, P= 0.54) (Table 6). The differ-
ence remained insigniﬁcant after stratiﬁcation of the groups
by exposure, which was performed to exclude the interaction
effect (Tables 7a and 7b).
Moreover, the frequency of GSTT1 Null-genotype was
compared in both sample groups; a frequency of 24% was
found in asthmatic workers and 10% in controls and the dif-
ference was of a border line signiﬁcance (P= 0.06) (Table
6). Stratiﬁcation of the groups by exposure was done to ex-
clude the interaction effect; the difference remained non-signif-
icant (Tables 8a and 8b).
However, the study examined the association between com-
bined GSTM1/T1 Null-genotype and asthma phenotype and
showed that 20% of workers with bronchial asthma had acombined GSTM1/T1 Null-genotype compared to only 6%
of the controls; this difference was found to be statistically sig-
niﬁcant (OR 3.92, 95% CI: 0.9–19.4 and P= 0.037) (Table 9).
3.6. Correlation between eosinophil count, total serum IgE and
bronchodilator responsiveness in workers with bronchial asthma
A signiﬁcant positive correlation was found between total ser-
um IgE level and pre-bronchodilator FEV1/FVC% (r= 0.29
and P= 0.03). Moreover, A signiﬁcant positive correlation
was found between total serum IgE level and eosinophil count
(r= 0.38 and P= 0.00) (Figs. 2 and 3). On the other hand,
there was no signiﬁcant correlation between eosinophil count,
total serum IgE level and pre-bronchodilator FEV1 or FVC,
their absolute change, the mean% change from the initial
and the mean% change from the predicted values.
Table 8b Association between GSTM1 genotype proﬁle and bronchial asthma phenotype among non-exposed workers with
bronchial asthma and non-exposed controls.
Gene Chromosomal location Polymorphism Genotype Workers with BA (n= 10) Controls (n= 19) OR 95%CI P-value
No. (%) No. %
GSTT1 22q11 Null allele Null 3 (30%) 2 (10.5%) 3.64 0.49–26.7 0.18
WT 7 (70%) 17 (89.4%)
BA: Bronchial asthma.
serum total IgE (IU/ml) 
8006000400020000-2000
FE
V1
/F
VC
%
 (%
)
70
68
66
64
62
60
58
56
54
Figure 2 Correlation between total serum IgE level and pre-
bronchodilator FEV1/FVC% among workers with bronchial
asthma.
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Figure 3 Correlation between eosinophil count and total serum
IgE level among workers with bronchial asthma.
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and bronchodilator responsiveness in workers with bronchial
asthma
The association between GSTM1 Null-genotype and bron-
chodilator responsiveness was studied in workers with bron-
chial asthma. A total of 50 asthmatic patients were classiﬁed
according to their GSTM1 genotyping into two groups; the
ﬁrst group consisted of 29 workers with bronchial asthma
(58%) with GSTM1 Null-genotype and the second group
consisted of 21 workers with bronchial asthma with GSTM1
WT-genotype (42%). There was no signiﬁcant difference be-
tween the two groups regarding pre-bronchodilator FEV1,
FVC, FEV1/FVC%, FEV1 absolute change, FEV1% change
from the initial , FEV1% change from the predicted, FVC
absolute change, FVC% change from the initial, FVC%
change from the predicted, and FEV1/FVC% mean change
(Table 10).
Furthermore, the association between GSTT1 Null-geno-
type and bronchodilator responsiveness in workers with bron-
chial asthma was studied. A total of 50 asthmatic patients were
classiﬁed according to their GSTT1 genotyping into two
groups; the ﬁrst group consisted of 11 workers with bronchial
asthma (22%) with GSTT1 Null-genotype and the second
group consisted of 39 workers with bronchial asthma with
GSTT1 WT-genotype (78%). There was no signiﬁcant differ-
ence between the two groups regarding pre-bronchodilator
FEV1, FVC, FEV1/FVC%, their absolute and percent change
from initial and predicted values. (Table 11).4. Discussion
In the current study, exposure was found to be a signiﬁcant
risk factor in the development of bronchial asthma among
workers. Regarding the nature of exposure among workers
with bronchial asthma, signiﬁcantly increased ORs were found
for exposure to LMW, mixed environments, irritants, and
HMW allergens. This ﬁnding was consistent with that of a
study conducted by Kennedy et al.41; the study reported signif-
icantly increased ORs for exposure to all low molecular weight
agents combined (and in particular, to reactive chemicals and
industrial cleaning agents); and Odds ratios greater than 2.0
were found for exposure to bioaerosols, metals, and to mixed
environments.
In the present study, pre-bronchodilator FEV1, FVC and
FEV1/FVC% were signiﬁcantly lower in workers with bron-
chial asthma compared to controls. This ﬁnding was consistent
with results reported by a study conducted by Richter et al.33
where the mean percent predicted values of pre-bronchodilator
FEV1, FVC and FEV1/FVC% among asthmatic patients
were (59.29 ± 1.82%, 86.5 ± 2.74%, and 57.65 ± 1.16,
respectively). Moreover, it was concomitant with the result
of another study that was conducted to provide reference val-
ues for healthy adult population where the mean values of pre-
bronchodilator FEV1, FVC and FEV1/FVC% among general
adult population were (4.04 ± 0.56 L, 5.08 ± 0.75 L, and
80 ± 5%, respectively).42
Post-bronchodilator FEV1, FVC and FEV1/FVC% were
signiﬁcantly lower in workers with bronchial asthma com-
Table 9 Association between combined GSTM1/T1 Null-genotype and bronchial asthma phenotype.
GSTM1 and GSTT1 genotype Workers with BA (n= 50) Controls (n= 50) OR 95% CI P-value
GSTM Null and GSTT1 Null-genotype 10 (20%) 3 (6%) 3.92 0.9–19.4 0.037
GSTM1 WT and GSTT1 WT-genotype 20 (40%) 22 (44%) 0.78 0.32–1.87 0.542
GSTM1 Null and GSTT1 WT-genotype 19 (38%) 23 (46%) 0.72 0.3–1.72 0.418
GSTM1 WT and GSTT1 Null-genotype 1 (2%) 2 (4%) 1.0 0.1–10.47 1.0a
BA: Bronchial asthma.
a Fisher’s Exact test.
Table 10 Association between GSTM1 genotype and post-bronchodilator (Post-BD) change in lung function indices among workers
with bronchial asthma.
Lung function indices GSTM1 genotyping (Null alleles) (n= 50) Mann–Whitney test P-value
Null (n= 29) WT (n= 21)
X± SD X± SD
FEV1 Absolute change (L) 0.40 ± 0.16 0.44 ± 0.22 0.29
FEV1% change from initial 20.13 ± 8.73 21.66 ± 9.72 0.302
FEV1% change from predicted 12.66 ± 5.30 13.20 ± 5.59 0.381
FVC Absolute change (L) 0.38 ± 0.11 0.37 ± 0.15 0.821
FVC% change from initial 12.23 ± 3.83 11.46 ± 5.71 0.497
FVC% change from predicted 9.76 ± 2.82 9.39 ± 3.75 0.768
FEV1/FVC% mean change 4.41 ± 5.66 5.63 ± 7.32 0.26
FEV1/FVC% change from predicted 4.94 ± 6.51 6.51 ± 8.59 0.15
Table 11 Association between GSTT1 genotype and post-bronchodilator (Post-BD) change in lung function indices among workers
with bronchial asthma.
Lung function indices GSTT1 genotyping (Null alleles) (n= 50) Mann–Whitney test P-value
Null (n= 11) WT (n= 39)
X± SD X± SD
FEV1 absolute change (L) 0.51 ± 0.10 0.39 ± 0.20 0.15
FEV1% change from initial 26.09 ± 6.07 19.28 ± 9.30 0.07
FEV1% change from predicted 16.10 ± 3.12 11.98 ± 5.56 0.116
FVC Absolute change (L) 0.34 ± 6.44 0.39 ± 0.14 0.23
FVC% change from initial 10.28 ± 3.63 12.37 ± 4.86 0.291
FVC% change from predicted 8.81 ± 1.47 9.83 ± 3.58 0.386
FEV1/FVC% mean change 8.37 ± 2.35 3.95 ± 6.81 0.08
FEV1/FVC% change from predicted 9.78 ± 3.45 4.42 ± 7.89 0.08
62 N.S. Elshaer et al.pared to controls in the present study. This ﬁnding was con-
sistent with that of the study conducted by Richter et al.33 in
which, among bronchial asthmatic patient group in their
study, the mean percent predicted values of post-bronchodila-
tor FEV1 was 75 ± 2.1%, the mean absolute change of FEV1
was 0.445 ± 0.03 L), the mean% change of FEV1 from the
initial was 27 ± 3, the mean% change of FEV1 from the pre-
dicted was 15 ± 2%, the mean absolute change of FVC was
0.375 ± 0.05 L, the mean % change of FVC from the initial
was 13 ± 2% and the mean% change of FVC from the
predicted was 11 ± 2%. The ﬁnding of the present study
was also consistent with the ﬁnding of the study conducted
by Johannessen et al.42 in which the mean value of post-bron-
chodilator FEV1 was 4.12 ± 0.55 L, the mean absolute
change of FEV1 was 0.078 ± 0.12 L, the mean value of
post-bronchodilator FVC was 5.06 ± 0.75 L, and the mean
absolute change of FVC was 0.022 ± 0.13 L among healthy
adult population.Eosinophil count and total serum IgE were studied among
workers with bronchial asthma. There was no signiﬁcant dif-
ference between workers with bronchial asthma and controls
regarding eosinophil count and total serum IgE level in the
current study. This result was in agreement with the results
of some studies.43,44 On the other hand, it was inconsistent
with the results of other studies which concluded that in the
general population, the percentage of patients with asthma
and airway responsiveness is greater among those with high
IgE levels than among those with low IgE levels.45–47 More-
over, one group of authors reported that, among non-allergic
subjects, asthma is more prevalent in those with elevated IgE
levels than in those with normal IgE levels.48 Previous studies
have also suggested that elevated serum IgE levels are signiﬁ-
cantly associated with a higher frequency of symptoms in sub-
jects with asthma.49
In the current study, although there was a tendency for an
increase in the level of total serum IgE as the severity of asth-
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ries of bronchial asthma was statistically insigniﬁcant. Other
studies involving adult patients with asthma in Europe, re-
ported that total serum IgE was found to be a strong predictor
of moderate-to-severe asthma.50 In another study, higher total
IgE levels were shown to be associated with the degree of asth-
ma severity among younger subjects with difﬁcult-to-treat or
in those who were categorized as severe asthma.51
The present study presented the ﬁndings regarding the
homozygous deletions of the GSTM1 and GSTT1 genes.
There was at trend of higher frequency of GSTT1 Null-geno-
type in asthmatic workers relative to controls, 24% and
10%, respectively, but the difference was of border line signif-
icance [OR was 0.35 (95% CI: 0.10–1.21) and (P= 0.06)]. This
ﬁnding was consistent with that of the study conducted by
Hanene et al.52 aiming at assessing whether polymorphism of
GST genes (GSTM1 and GSTT1) are associated with asthma;
their study concluded that there was no signiﬁcant difference
between the group of bronchial asthma patients and controls
regarding the presence of GSTT1 null polymorophism
(37.5% and 29.5%, respectively, and P> 0.05).52 Similar re-
sults were reported in other studies.19,20,53,54 However, some
studies have suggested that individuals with the GSTT1*0/*0
(GSTT1 null) genotype are more susceptible to genotoxic dam-
age and lung diseases than individuals with the GSTT1
gene.55,56
Furthermore, the GSTM1 null polymorphism was present
in 58% of workers with bronchial asthma and in 52% of con-
trols; the difference was statistically insigniﬁcant [OR was 0.78
(95% CI: 0.33–1.86) and (P= 0.54)]. This ﬁnding was consis-
tent with that of a study conducted by Sandford et al.57 On the
other hand, it was inconsistent with the ﬁnding reported by
Hanene et al.;52 where the GSTM1 Null-genotype was signiﬁ-
cantly associated with an increased risk of asthma in which
GSTM1 Null-genotype was present among 70.7% of the asth-
matic patients and among 50.2% of the control group in their
study (P= 0.02). Moreover, other studies have demonstrated
a signiﬁcant association between subjects lacking GSTM1
activity and the risk of developing bronchial asthma and/or
other forms of lung disease.17,19,53,55,58,59
The difference in the results might be due to the difference
in sample size or type of population and frequency of Null-
genotype in Egyptians. For example, in the present study,
the frequency of GSTM1 Null-genotype among controls was
52%; this ﬁnding was similar to the frequency previously re-
ported by Hamdy et al.60 and Saad et al.61 (55.5% and
42.5%, respectively). Regarding the frequency of GSTT1
Null-genotype among controls, in the present study it was
10% which was close to that reported by Saad et al.
(16%).61 However, a slightly higher frequency was reported
by Hamdy et al. (29.5%).60
In 2007, a literature-based meta-analysis aiming at studying
genetic polymorphism of GSTM1 and GSTT1 and bronchial
asthma was published. The meta-analysis included 14 studies,
involving a total of 2292 asthma patients and 5718 controls.
The OR of the asthma risk associated with GSTM1 Null-geno-
type was 1.20 (95% CI: 1.08–1.35). The GSTT1 Null-genotype
was not associated with asthma risk except after stratiﬁcation
of the groups by smoking; it was associated with asthma risk in
non-smoker adults (OR = 2.06, 95% CI: 1.21–3.71).62
The meta-analysis entailed further analysis combining the
GSTT1 and GSTM1 genotypes. Subjects with Null-genotypesfor both GSTM1 and GSTT1 were at a signiﬁcant higher risk
for developing asthma (OR= 2.15, 95% CI: 1.39–3.33) com-
pared to subjects who had both active genes62; this ﬁnding
was consistent with the ﬁnding of the present study (OR
3.92, 95%CI: 0.9–19.4 and P= 0.037). The meta-analysis sug-
gested that there is an additive effect for GSTT1 and GSTM1
genotypes,62 which is in agreement with the results of the cur-
rent study.
The results of the meta-analysis suggest that the GSTT1
and GSTM1 Null-genotypes may play an important role in
asthma pathogenesis. It is possible that intermediate electro-
philic metabolites, arising in the ﬁrst phase of detoxiﬁcation,
are not metabolized by GST enzymes in asthmatic patients
and are not excreted. These intermediate metabolites may
damage cells and generate oxidative stress, and so contribute
to the pathogenesis of asthma.62
On the other hand, another recent meta-analysis conducted
by Minelli et al. in 2009 and entailed meta-analyses of GSTM1
(n= 22 studies) and GSTT1 (n= 19) showed an increased
asthma risk associated with the Null-genotype; however, the
association disappeared when meta-analysis was restricted to
the largest studies.63
In the present study, a signiﬁcant positive correlation was
found between total serum IgE level and eosinophil count.
Although this ﬁnding was consistent with that of another
study,64 it was inconsistent with the result of Razi et al.44
who found no statistical difference between asthma patients
with high and low total serum IgE levels in their peripheral
blood eosinophil count (P= 0.72). Moreover, the current
study found a signiﬁcant positive correlation between total ser-
um IgE level and pre-bronchodilator FEV1/FVC%. This result
was inconsistent with that of a longitudinal study where a sig-
niﬁcant inverse association was found between total serum IgE
levels and FEV1/FVC%; the authors suggested that higher IgE
levels indicate the presence of a disease process that can in-
volve inﬂammation or other mechanisms related to IgE pro-
duction which can impair lung function over time.65
On the other hand, the present study found no signiﬁcant
correlations between eosinophil count or total serum IgE
and pre-bronchodilator FEV1, FVC, FEV1/FVC%, their
absolute and percent change from initial and predicted val-
ues. This ﬁnding was consistent with that of the study con-
ducted by Razi et al.44 However, it was in contrast to
ﬁndings reported by Endoh et al. who concluded that higher
serum IgE levels are correlated with lower values of FEV1,
which is related to airway tone, and possibly act via cholin-
ergic mechanisms.66 Moreover, other authors have reported
that, among patients with asthma, mean FEV1 is signiﬁ-
cantly lower in those with high IgE levels than in those with
low IgE levels.67
In conclusion, the present study demonstrated that occupa-
tional exposure is a signiﬁcant risk factor for the occurrence of
bronchial asthma among workers. Moreover, it concluded
that eosinophil count as well as total serum IgE neither pre-
dicts the occurrence of bronchial asthma nor affects the sever-
ity and pattern of the disease among workers with bronchial
asthma. Though there was a trend of higher frequency of
GSTT1 Null-genotype in asthmatic workers relative to con-
trols, the difference was of border line signiﬁcance; however,
combined GSTT1 and GSTM1 Null-genotypes was consid-
ered as a potential risk factor for the development of bronchial
asthma.
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